YARW Yarrow Bioscience, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1566044 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.1%
TTM net income YoY-35.6%
TTM EPS YoY-1,140.7%
Revenue 3-yr CAGR-12.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,949.6%
Net margin-8,097.7%
FCF margin—
EBITDA margin—
Returns
ROE-67.8%
ROA-58.7%
ROIC (approx.)-108.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $570,000 | $501,000 |
| R&D expense | $19.24M | $30.95M |
| SG&A expense | $11.08M | $13.19M |
| Operating income | -$29.75M | -$43.64M |
| Pretax income | -$26.73M | -$39.80M |
| Income tax | $4,000 | $4,000 |
| Net income | -$26.48M | -$39.83M |
| EBITDA | -$29.73M | -$43.63M |
| EPS (basic) | -0.62 | -0.93 |
| EPS (diluted) | -0.62 | -0.93 |
| Weighted avg. shares (diluted) | 42.77M | 42.59M |
| Balance sheet | ||
| Cash & equivalents | $99.99M | $19.93M |
| Short-term investments | $4.98M | $41.59M |
| Current assets | $100.00M | $64.44M |
| PP&E, net | $0 | $113,000 |
| Total assets | $100.41M | $66.91M |
| Current liabilities | $71.55M | $14.82M |
| Long-term debt | $0 | $0 |
| Total debt | $0 | $0 |
| Total liabilities | $71.55M | $14.82M |
| Shareholders' equity | -$70.99M | $52.09M |
| Net debt | -$99.99M | -$19.93M |
| Shares outstanding | 3.05M | 14.83M |
| Cash flow statement | ||
| Operating cash flow | -$33.12M | -$33.97M |
| Capital expenditure | $0 | $117,000 |
| Free cash flow | -$33.12M | -$34.09M |
| Investing cash flow | $37.37M | $23.36M |
| Financing cash flow | -$143,000 | -$141,000 |
| Depreciation & amortization | $23,000 | $4,000 |
| Stock-based compensation | $2.31M | $3.30M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.